Patents by Inventor Edward Giovannucci

Edward Giovannucci has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Circulating insulin-like growth factor-I, insulin-like growth factor binding protein-3 and prostate cancer risk
    Patent number: 6645770
    Abstract: Methods of predicting a propensity to developing prostate cancer are presented. The method consists of measuring the IGF status of individual. Individuals with high IGF status, as compared with normal reference range values, are at increased risk for developing prostate cancer. More particularly, the IGF status may be determined by measuring IGF-I levels and/or IGFBP-3 levels. High IGF and low IGFBP levels are indicative of a high IGF status. A method of determining the prognosis of existing prostate cancers or of monitoring disease progression involves determining the IGF/PSA status of an individual. Individuals with a high IGF/PSA status (both high IGF status and high PSA levels) tend to develop severe prostate cancer and have a poorer overall prognosis.
    Type: Grant
    Filed: March 14, 2001
    Date of Patent: November 11, 2003
    Assignees: The Brigham & Women's Hospital, Inc., Lady Davis Institute
    Inventors: Michael N. Pollak, Meir J. Stampfer, Edward Giovannucci
  • Circulating insulin-like growth factor-I and prostate cancer risk
    Publication number: 20030044860
    Abstract: Methods of predicting a propensity to developing prostate cancer are presented. The method consists of measuring the IGF status of individual. Individuals with high IGF status, as compared with normal reference range values, are at increased risk for developing prostate cancer. More particularly, the IGF status may be determined by measuring IGF-I levels and/or IGFBP-3 levels. High IGF and low IGFBP levels are indicative of a high IGF status. A method of determining the prognosis of existing prostate cancers or of monitoring disease progression involves determining the IGF/PSA status of an individual. Individuals with a high IGF/PSA status (both high IGF status and high PSA levels) tend to develop severe prostate cancer and have a poorer overall prognosis.
    Type: Application
    Filed: December 18, 2001
    Publication date: March 6, 2003
    Applicant: Lady Davis Institute
    Inventors: Michael N. Pollak, Meir J. Stampfer, Edward Giovannucci
  • Circulating insulin-like growth factor-I and prostate cancer risk
    Patent number: 6410335
    Abstract: Methods of predicting a propensity to developing prostate cancer are presented. The consists of measuring the IGF status of individual. Individuals with high IGF status, as compared with normal reference range values, are at increased risk for developing prostate cancer. More particularly, the IGF status may be determined by measuring IGF-I levels and/or IGFBP-3 levels. High IGF and low IGFBP levels are indicative of a high IGF status. A method of determining the prognosis of existing prostate cancers or of monitoring disease progression involves determining the IGF/PSA status of an individual. Individuals with a high IGF/PSA staus (both high IGF status and high PSA levels) tend to develop severe prostate cancer and have a porrer overall prognosis.
    Type: Grant
    Filed: January 21, 1999
    Date of Patent: June 25, 2002
    Assignees: The Brigham and Woman's Hospital, Inc., Sir Mortimer B. Davis - Jewish General Hospital Foundation
    Inventors: Michael N. Pollak, Meir J. Stampfer, Edward Giovannucci
  • Method for predicting the risk of prostate cancer morbidity and mortality
    Patent number: 6300060
    Abstract: There is described a method for prognosis of prostate cancer in a male comprising: (a) determining the length of the CAG trinucleotide repeat of exon 1 of the androgenic receptor gene and/or the length of the TA dinucleotide repeat of the 5 alpha reductase Type II gene or its complement obtained from DNA of the male and (b) correlating the length of the repeat with the aggressiveness and mortality risk of the cancer in the male.
    Type: Grant
    Filed: May 16, 1996
    Date of Patent: October 9, 2001
    Assignees: Dana-Farber Cancer Institute, Inc., The Brigham and Women's Hospital, Inc.
    Inventors: Philip W. Kantoff, Myles Brown, Edward Giovannucci
  • Circulating insulin-like growth factor-I and prostate cancer risk
    Publication number: 20010018190
    Abstract: Methods of predicting a propensity to developing prostate cancer are presented. The method consists of measuring the IGF status of individual. Individuals with high IGF status, as compared with normal reference range values, are at increased risk for developing prostate cancer. More particularly, the IGF status may be determined by measuring IGF-I levels and/or IGFBP-3 levels. High IGF and low IGFBP levels are indicative of a high IGF status. A method of determining the prognosis of existing prostate cancers or of monitoring disease progression involves determining the IGF/PSA status of an individual. Individuals with a high IGF/PSA status (both high IGF status and high PSA levels) tend to develop severe prostate cancer and have a poorer overall prognosis.
    Type: Application
    Filed: March 14, 2001
    Publication date: August 30, 2001
    Inventors: Michael N. Pollak, Meir J. Stampfer, Edward Giovannucci